ABCC11 expression is regulated by estrogen in MCF7 cells, correlated with estrogen receptor α expression in postmenopausal breast tumors and overexpressed in tamoxifen-resistant breast cancer cells

Endocrine-Related Cancer

Volumn 15, Issue 1, 2008, Pages 125-138

  Honorat, Mylène ^a,b,c   Mesnier, Aurelia ^a,b,c   Vendrell, Julie ^a,b,c   Guitton, Jérôme ^a,d   Bieche, Ivan ^b,e   Lidereau, Rosette ^b,e   Kruh, Gary D ^f   Dumontet, Charles ^a,b,c   Cohen, Pascale ^a,b,c   Payen, Lea ^a,b,c  

^a UNIVERSITÉ LYON 1   (France)

^b INSERM   (France)

^c CENTRE LÉON BÉRARD   (France)

^d CENTRE HOSPITALIER LYON SUD   (France)

^e CENTRE RENÉ HUGUENIN   (France)

^f UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FLUOROURACIL; FULVESTRANT; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 8; TAMOXIFEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CELL; CANCER RESISTANCE; CELL STRAIN MCF 7; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; DRUG EXPOSURE; DRUG SENSITIVITY; FEMALE; HORMONAL REGULATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PROTEIN EXPRESSION; UPREGULATION;

EID: 41349092741     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/ERC-07-0189     Document Type: Article

References (45)

1. Acconcia F & Kumar R 2006 Signaling regulation of genomic and nongenomic functions of estrogen receptors. Cancer Letters 238 1-14.
2. Annereau JP, Szakacs G, Tucker CJ, Arciello A, Cardarelli C, Collins J, Grissom S, Zeeberg BR, Reinhold W, Weinstein JN et al. 2004 Analysis of ATP-binding cassette transporter expression in drug-selected cell lines by a microarray dedicated to multidrug resistance. Molecular Pharmacology 66 1397-1405.
3. Badia E, Duchesne MJ, Semlali A, Fuentes M, Giamarchi C, Richard-Foy H, Nicolas JC & Pons M 2000 Long-term hydroxytamoxifen treatment of an MCF-7-derived breast cancer cell line irreversibly inhibits the expression of estrogenic genes through chromatin remodeling. Cancer Research 60 4130-4138.
4. Bera TK, Lee S, Salvatore G, Lee B & Pasten I 2001 MRP8, a new member of ABC transporter superfamily, identified by EST database mining and gene prediction program, is highly expressed in breast cancer. Molecular Medicine 7 509-516.
5. Berry M, Nunez AM & Chambon P 1989 Estrogen-responsive element of the human pS2 gene is an imperfectly palindromic sequence. PNAS 86 1218-1222.
6. Bieche I, Girault I, Urbain E, Tozlu S & Lidereau R 2004 Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma. Breast Cancer Research 6 R252-R263.
7. Biswas DK, Singh S, Shi Q, Pardee AB & Iglehart JD 2005 Crossroads of estrogen receptor and NF-κ signaling. Science's STKE 2005 pe27.
8. Bloom HJ & Richardson WW 1957 Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. British Journal of Cancer 11 359-377.
9. Bortfeld M, Rius M, Konig J, Herold-Mende C, Nies AT & Keppler D 2006 Human multidrug resistance protein 8 (MRP8/ABCC11), an apical efflux pump for steroid sulfates, is an axonal protein of the CNS and peripheral nervous system. Neuroscience 137 1247-1257.
10. Burger H, Foekens JA, Look MP, Meijer-van Gelder ME, Klijn JG, Wiemer EA, Stoter G & Nooter K 2003 RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clinical Cancer Research 9 827-836.
11. Chen ZS, Guo Y, Belinsky MG, Kotova E & Kruh GD 2005 Transport of bile acids, sulfated steroids, estradiol 17-beta-D-glucuronide, and leukotriene C4 by human multidrug resistance protein 8 (ABCC11). Molecular Pharmacology 67 545-557.
12. Demirpence E, Duchesne MJ, Badia E, Gagne D & Pons M 1993 MVLN cells: a bioluminescent MCE-7-derived cell line to study the modulation of estrogenic activity. Journal of Steroid Biochemistry and Molecular Biology 46 355-364.
13. Dorssers LC, Van der Flier S, Brinkman A, van Agthoven T, Veldscholte J, Berns EM, Klijn JG, Beex LV & Foekens JA 2001 Tamoxifen resistance in breast cancer: elucidating mechanisms. Drugs 61 1721-1733.
14. Ee PL, He X, Ross DD & Beck WT 2004a Modulation of breast cancer resistance protein (BCRP/ABCG2) gene expression using RNA interference. Molecular Cancer Therapeutics 3 1577-1583.
15. Ee PL, Kamalakaran S, Tonetti D, He X, Ross DD & Beck WT 2004b Identification of a novel estrogen response element in the breast cancer resistance protein (ABCG2) gene. Cancer Research 64 1247-1251.
16. Garcia M, Derocq D, Freiss G & Rochefort H 1992 Activation of estrogen receptor transfected into a receptor-negative breast cancer cell line decreases the metastatic and invasive potential of the cells. PNAS 89 11538-11542.
17. Girault I, Bieche I & Lidereau R 2006 Role of estrogen receptor alpha transcriptional coregulators in tamoxifen resistance in breast cancer. Maturitas 54 342-351.
18. Guo Y, Kotova E, Chen ZS, Lee K, Hopper-Borge E, Belinsky MG & Kruh GD 2003 MRP8, ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2′,3′- dideoxycytidine and 9′-(2′-phosphonylmethoxyethyl)adenine. Journal of Biological Chemistry 278 29509-29514.
19. Hall JM & McDonnell DP 2005 Coregulators in nuclear estrogen receptor action: from concept to therapeutic targeting. Molecular Interventions 5 343-357.
20. Howell A 2006 Pure oestrogen antagonists for the treatment of advanced breast cancer. Endocrine-Related Cancer 13 689-706.
21. Imai Y, Ishikawa E, Asada S & Sugimoto Y 2005 Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2. Cancer Research 65 596-604.
22. Jordheim LP, Cros E, Gouy MH, Galmarini CM, Peyrottes S, Mackey J, Perigaud C & Dumontet C 2004 Characterization of a gemcitabine-resistant murine leukemic cell line: reversion of in vitro resistance by a mononucleotide prodrug. Clinical Cancer Research 10 5614-5621.
23. Kathleen IP 2002 Prognostic and predictive factors for individualized therapy. 3rd International BCIRG Conference.
24. Kruh GD, Guo Y, Hopper-Borge E, Belinsky MG & Chen ZS 2007 ABCC10, ABCC11, and ABCC12. Pflugers Archiv 453 675-684.
25. Laganiere J, Deblois G, Lefebvre C, Bataille AR, Robert F & Giguere V 2005 From the cover: location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response. PNAS 102 11651-11656.
26. Larkin A, O'Driscoll L, Kennedy S, Purcell R, Moran E, Crown J, Parkinson M & Clynes M 2004 Investigation of MRP-1 protein and MDR-1 P-glycoprotein expression in invasive breast cancer: a prognostic study. International Journal of Cancer 112 286-294.
27. Lin CY, Strom A, Vega VB, Kong SL, Yeo AL, Thomsen JS, Chan WC, Doray B, Bangarusamy DK, Ramasamy A et al. 2004 Discovery of estrogen receptor alpha target genes and response elements in breast tumor cells. Genome Biology 5 R66.
28. Liu H, Cheng D, Weichel AK, Osipo C, Wing LK, Chen B, Louis TE & Jordan VC 2006 Cooperative effect of gefitinib and fumitremorgin c on cell growth and chemosensitivity in estrogen receptor alpha negative fulvestrant-resistant MCF-7 cells. International Journal of Oncology 29 1237-1246.
29. Ma XJ, Wang Z, Ryan PD, Isakoff SJ, Barmettler A, Fuller A, Muir B, Mohapatra G, Salunga R, Tuggle JT et al. 2004 A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5 607-616.
30. McCallum HM & Lowther GW 1996 Long-term culture of primary breast cancer in defined medium. Breast Cancer Research and Treatment 39 247-259.
31. McGuire WL 1986 In Hormone Receptors in Breast Cancer, Cancer Surveys, vol 5, pp. 527 536. Ed RD Bulbrook. Oxford University Press: Oxford, UK.
32. McKenna NJ & O'Malley BW 2002 Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 108 465-474.
33. Milano A, Dal Lago L, Sotiriou C, Piccart M & Cardoso F 2006 What clinicians need to know about antioestrogen resistance in breast cancer therapy. European Journal of Cancer 42 2692-2705.
34. Oguri T, Bessho Y, Achiwa H, Ozasa H, Maeno K, Maeda H, Sato S & Ueda R 2007 MRP8/ABCC11 directly confers resistance to 5-fluorouracil. Molecular Cancer Therapeutics 6 122-127.
35. Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ & Scanlan TS 1997 Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 277 1508-1510.
36. Park S, Shimizu C, Shimoyama T, Takeda M, Ando M, Kohno T, Katsumata N, Kang YK, Nishio K & Fujiwara Y 2006 Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Research 1 9-17.
37. Parker WB & Cheng YC 1990 Metabolism and mechanism of action of 5-fluorouracil. Pharmacology and Therapeutics 48 381-395.
38. Pratt S, Shepard RL, Kandasamy RA, Johnston PA, Perry W III & Dantzig AH 2005 The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites. Molecular Cancer Therapeutics 4 855-863.
39. Ross JS & Fletcher JA 1998 The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist 3 237-252.
40. Smith CL & O'Malley BW 2004 Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocrine Reviews 25 45-71.
41. Szakacs G, Annereau JP, Lababidi S, Shankavaram U, Arciello A, Bussey KJ, Reinhold W, Guo Y, Kruh GD, Reimers M et al. 2004 Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell 6 129-137.
42. Tozlu S, Girault I, Vacher S, Vendrell J, Andrieu C, Spyratos F, Cohen P, Lidereau R & Bieche I 2006 Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach. Endocrine-Related Cancer 13 1109-1120.
43. Vendrell JA, Magnino F, Danis E, Duchesne MJ, Pinloche S, Pons M, Birnbaum D, Nguyen C, Theillet C & Cohen PA 2004 Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation. Journal of Molecular Endocrinology 32 397-414.
44. Vendrell JA, Bieche I, Desmetz C, Badia E, Tozlu S, Nguyen C, Nicolas JC, Lidereau R & Cohen PA 2005 Molecular changes associated with the agonist activity of hydroxy-tamoxifen and the hyper-response to estradiol in hydroxy-tamoxifen-resistant breast cancer cell lines. Endocrine-Related Cancer 12 75-92.
45. Wang H, Zhou L, Gupta A, Vethanayagam RR, Zhang Y, Unadkat JD & Mao Q 2005 Regulation of BCRP/ABCG2 expression by progesterone and 17β-estradiol in human placental BeWo cells. American Journal of Physiology. Endocrinology and Metabolism 290 E798-E807.